MX2023009961A - Compuestos heterociclicos antivirales. - Google Patents

Compuestos heterociclicos antivirales.

Info

Publication number
MX2023009961A
MX2023009961A MX2023009961A MX2023009961A MX2023009961A MX 2023009961 A MX2023009961 A MX 2023009961A MX 2023009961 A MX2023009961 A MX 2023009961A MX 2023009961 A MX2023009961 A MX 2023009961A MX 2023009961 A MX2023009961 A MX 2023009961A
Authority
MX
Mexico
Prior art keywords
hrsv
present
compounds
hmpv
heterocyclic compounds
Prior art date
Application number
MX2023009961A
Other languages
English (en)
Inventor
In Jong Kim
Yat Sun Or
Jianming Yu
Xiben Li
Long Nguyen
Kevin Mcgrath
Adam Szymaniak
Tyler J Mann
Robert Leon
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MX2023009961A publication Critical patent/MX2023009961A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención describe compuestos de la Fórmula (I), o sales, ésteres, o profármacos farmacéuticamente aceptables de los mismos: (ver Fórmula), que inhiben los inhibidores del virus sincitial respiratorio humano (HRSV) o del metapneumovirus humano (HMPV). La presente invención se refiere además a las composiciones farmacéuticas que comprenden los compuestos antes mencionados para la administración a un sujeto que padece de infección por HRSV o HMPV. La invención se refiere además con métodos para tratar una infección por HRSV o HMPV en un sujeto mediante la administración de una composición farmacéutica que comprende los compuestos de la presente invención.
MX2023009961A 2021-02-26 2022-02-24 Compuestos heterociclicos antivirales. MX2023009961A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163154318P 2021-02-26 2021-02-26
US202163168705P 2021-03-31 2021-03-31
US202163171895P 2021-04-07 2021-04-07
US202163293339P 2021-12-23 2021-12-23
PCT/US2022/017686 WO2022182861A1 (en) 2021-02-26 2022-02-24 Antiviral heterocyclic compounds

Publications (1)

Publication Number Publication Date
MX2023009961A true MX2023009961A (es) 2023-09-05

Family

ID=83049649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009961A MX2023009961A (es) 2021-02-26 2022-02-24 Compuestos heterociclicos antivirales.

Country Status (12)

Country Link
US (1) US11945830B2 (es)
EP (1) EP4298103A1 (es)
JP (1) JP2024507561A (es)
KR (1) KR20230161976A (es)
AU (1) AU2022227674A1 (es)
BR (1) BR112023016970A2 (es)
CA (1) CA3173354A1 (es)
IL (1) IL305189A (es)
MX (1) MX2023009961A (es)
TW (1) TW202300144A (es)
UY (1) UY39642A (es)
WO (1) WO2022182861A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505558B1 (en) * 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011052A (es) 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
WO2003101968A1 (fr) * 2002-05-31 2003-12-11 Eisai Co., Ltd. Compose de pyrazole et composition medicinale le contenant
NZ570344A (en) 2002-09-20 2010-04-30 Arrow Therapeutics Ltd Benzodiazepine derivatives and pharmaceutical compositions containing them
WO2004052348A2 (en) * 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
CA2541618C (en) 2003-10-30 2011-12-13 Boehringer Ingelheim (Canada) Ltd. Rsv polymerase inhibitors
GB0406282D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
GB0406279D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
GB0406280D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
WO2006041970A2 (en) 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
KR101512477B1 (ko) 2006-07-13 2015-04-15 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 사용되는 4-아미노-4-옥소부타노일 펩티드
EP2086966B1 (en) 2006-11-17 2011-09-14 GlaxoSmithKline LLC 2-carboxy thiophene derivatives as anti viral agents
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8999969B2 (en) 2009-07-09 2015-04-07 Gilead Sciences, Inc. Anti-RSV compounds
ES2564318T3 (es) 2009-11-05 2016-03-21 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
EP2545050B1 (en) * 2010-03-10 2014-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
EA201590020A1 (ru) 2012-06-15 2015-03-31 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
KR20150028969A (ko) 2012-06-15 2015-03-17 얀센 알 앤드 디 아일랜드 호흡기 합포체 바이러스의 항바이러스제로서의 벤즈이미다졸로 치환된 4-치환된 1,3-디하이드로-2h-벤즈이미다졸-2-온 유도체
KR20150046259A (ko) 2012-08-23 2015-04-29 앨리오스 바이오파마 인크. 파라믹소바이러스 바이러스성 감염의 치료용 화합물
LT2909195T (lt) 2012-10-16 2017-09-25 Janssen Sciences Ireland Uc Antivirusiniai rsv junginiai
KR102254837B1 (ko) 2013-01-28 2021-05-24 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 호흡기 합포체 바이러스의 항바이러스제로서의 퀴녹살리논 및 디하이드로퀴녹살리논
SG11201600977XA (en) 2013-08-21 2016-03-30 Alios Biopharma Inc Antiviral compounds
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
EP3177299A4 (en) 2014-08-05 2018-04-04 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
SG11201701184WA (en) 2014-10-10 2017-03-30 Pulmocide Ltd Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
EP3233867B1 (en) 2014-12-18 2018-10-17 Pulmocide Limited 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
WO2017015449A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
WO2017123884A1 (en) 2016-01-15 2017-07-20 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
MA44007A (fr) 2016-02-05 2018-12-19 Denali Therapeutics Inc Inhibiteurs du récepteur interagissant avec protéine kinase 1
WO2017175000A1 (en) 2016-04-08 2017-10-12 Pulmocide Limited Compounds
WO2018129287A1 (en) 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
KR102573499B1 (ko) 2017-02-16 2023-08-31 이난타 파마슈티칼스, 인코포레이티드 벤조디아제핀 유도체의 제조 방법
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US10881666B2 (en) 2017-09-29 2021-01-05 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
CN109966244A (zh) 2017-12-27 2019-07-05 天津耀辰实业发展有限公司 一种含有乐特莫韦的药物组合物
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
EP4037688A4 (en) 2019-10-04 2023-09-06 Enanta Pharmaceuticals, Inc. ANTIVIRAL HETEROCYCLIC COMPOUNDS
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents

Also Published As

Publication number Publication date
IL305189A (en) 2023-10-01
BR112023016970A2 (pt) 2023-10-10
UY39642A (es) 2022-09-30
US20230108803A1 (en) 2023-04-06
KR20230161976A (ko) 2023-11-28
JP2024507561A (ja) 2024-02-20
CA3173354A1 (en) 2022-09-01
US11945830B2 (en) 2024-04-02
AU2022227674A1 (en) 2023-09-21
WO2022182861A1 (en) 2022-09-01
TW202300144A (zh) 2023-01-01
EP4298103A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
MX2022003984A (es) Compuestos heterociclicos antivirales.
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
MX2023007192A (es) Inhibidores de prmt5.
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
PH12018550148A1 (en) Hepatitis b antiviral agents
MX2022010011A (es) Inhibidores de prmt5 novedosos.
PH12020550065A1 (en) Hepatitis b antiviral agents
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021011144A (es) Derivados de las benzodiazepinas como inhibidores del vsr.
MX2022012056A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento.
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2023009961A (es) Compuestos heterociclicos antivirales.
BR112022006298A2 (pt) Compostos heterocíclicos antivirais